In July 2021, it was announced that Gilead-partnered Teneobio, Inc. had been acquired by Amgen for a reported $2.5 Billion cash transaction. With both Amgen and Gilead having been SBIR-involved themselves in their early days, Tenebio is a biotechnology company developing a new class of biologics - Human Heavy Chain Antibodies (UniAbs) - used in treatments of cancer, autoimmunity, and infectious diseases. Teneobios discovery platform - TeneoSeek - comprises genetically engineered animals (UniRat® and OmniFlic®), next-generation sequencing, bioinformatics and high-throughput vector assembly technologies. TeneoSeek rapidly identifies large numbers of unique binding molecules specific for therapeutic targets of interest. Versatile antibody variable domains (UniDabs) derived from UniAbs can be assembled into multi-specific and multivalent therapeutic proteins, surpassing limitations of conventional antibody therapeutics. Teneobios plug-and-play T-cell engaging platform includes a diverse set of anti-CD3 antibodies for therapeutics with optimal efficacy and reduced toxicity. The firm has a strategic alliance with TESARO to develop the next generation of immuno-oncology,multispecific antibodies
